journal article·2026-04-06Open access

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration

Marianna T. P. Favaro, Eric Voltà-Durán, Julieta M. Sánchez, Elvira Escribano-Ferrer, Vanesa Huaca, Eva Miranda-Tovar, Ugutz Unzueta, Eloi Parladé, Esther Vázquez, Ramon Mangues, Antonio Villaverde, Isolda Casanova

ACS Materials Letters· Volume 8· Issue 4

Abstract

High Resolution Image Download MS PowerPoint Slide The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the Clostridium perfringens enterotoxin, enabled a systematic evaluation of transdermal penetration in mouse models. Whereas plain and R9-functionalized granules showed restricted permeation, c-CPE-functionalized granules achieved consistent distribution through the dermis into the hypodermal layers. These findings establish self-assembled protein amyloids as a promising and adaptable class of biomaterials for dermal protein delivery. Also, the ability of c-CPE to enhance permeability without auxiliary adjuvants, lipids, or invasive methods highlights the translational potential of this system for clinically applicable, noninvasive management of cutaneous conditions.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · RNA Interference and Gene Delivery · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institut de Biotecnologia i de Biomedicina (IBB)

Universitat Autònoma de Barcelona

Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina

Instituto de Salud Carlos III

Departament d’Òptica i Optometria

Universitat Politècnica de Catalunya − BarcelonaTech

Instituto de Investigaciones Biológicas y Tecnológicas (IIByT)

CONICET-Universidad Nacional de Córdoba

Departamento de Química, Cátedra de Química Biológica, Facultad de Ciencias Exactas, Físicas y Naturales, ICTA, Universidad Nacional de Córdoba, Av. Vélez Sársfield 1611, 5016 Córdoba, Argentina

Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences

University of Barcelona

Institute of Nanoscience and Nanotechnology (IN2UB)

Institut de Recerca Sant Pau (IR SANT PAU)

Josep Carreras Leukaemia Research Institute (IJC)

Departament de Genètica i de Microbiologia

Funding

Ministerio de Universidades · Agencia Estatal de Investigaci?n · Centro de Investigaci?n Biom?dica en Red en Bioingenier?a, Biomateriales y Nanomedicina · European Regional Development Fund · Ag?ncia de Gesti? d'Ajuts Universitaris i de Recerca · NextGenerationEU · Instituto de Salud Carlos III · Ministry of Science

References (86)

Show source-provided references
1. 10.1016/S0378-5173(01)00731-110.1016/S0378-5173(01)00731-1 ↗
2. 10.1039/c0cp02943b10.1039/c0cp02943b ↗
3. 10.1097/01.ASW.0000818572.31307.7b10.1097/01.ASW.0000818572.31307.7b ↗
4. 10.1111/j.1365-4632.2011.05311.x10.1111/j.1365-4632.2011.05311.x ↗
5. 10.1007/978-3-031-13505-7_4010.1007/978-3-031-13505-7_40 ↗
6. 10.1038/jid.2013.44610.1038/jid.2013.446 ↗
7. 10.1016/j.jaad.2006.05.04810.1016/j.jaad.2006.05.048 ↗
8. 10.1038/jid.2013.51310.1038/jid.2013.513 ↗
9. 10.1001/jamadermatol.2016.553810.1001/jamadermatol.2016.5538 ↗
10. 10.1691/ph.2023.301110.1691/ph.2023.3011 ↗
11. 10.1016/j.medidd.2023.10016210.1016/j.medidd.2023.100162 ↗
12. 10.1016/j.addr.2003.10.02810.1016/j.addr.2003.10.028 ↗
13. 10.1016/j.biomaterials.2022.12143510.1016/j.biomaterials.2022.121435 ↗
14. 10.7150/thno.6999910.7150/thno.69999 ↗
15. 10.1016/j.msec.2021.11222610.1016/j.msec.2021.112226 ↗
16. 10.1007/978-3-662-47862-2/COVER10.1007/978-3-662-47862-2/COVER ↗
17. 10.1007/s40139-021-00227-z10.1007/s40139-021-00227-z ↗
18. 10.1517/17425255.2012.63791610.1517/17425255.2012.637916 ↗
19. 10.2147/IJN.S59610.2147/IJN.S596 ↗
20. 10.1039/D2NA00530A10.1039/D2NA00530A ↗
21. 10.1002/anie.20210796010.1002/anie.202107960 ↗
22. 10.3390/pharmaceutics1502065610.3390/pharmaceutics15020656 ↗
23. 10.3390/pharmaceutics1601003410.3390/pharmaceutics16010034 ↗
24. 10.1016/j.jconrel.2023.02.00610.1016/j.jconrel.2023.02.006 ↗
25. 10.1002/advs.20190242010.1002/advs.201902420 ↗
26. 10.1016/j.apmt.2024.10234810.1016/j.apmt.2024.102348 ↗
27. 10.1021/acsami.4c0121010.1021/acsami.4c01210 ↗
28. 10.1016/bs.pmbts.2024.03.00910.1016/bs.pmbts.2024.03.009 ↗
29. 10.1021/acs.langmuir.5c0323810.1021/acs.langmuir.5c03238 ↗
30. 10.1038/srep2337010.1038/srep23370 ↗
31. 10.1126/science.117315510.1126/science.1173155 ↗
32. 10.1016/j.biotechadv.2021.10781710.1016/j.biotechadv.2021.107817 ↗
33. 10.1016/j.tibs.2020.08.00310.1016/j.tibs.2020.08.003 ↗
34. 10.1080/10717544.2021.199824910.1080/10717544.2021.1998249 ↗
35. 10.1002/advs.20230942710.1002/advs.202309427 ↗
36. 10.2217/nnm.13.4310.2217/nnm.13.43 ↗
37. 10.1088/0957-4484/28/1/01510210.1088/0957-4484/28/1/015102 ↗
38. 10.2217/nnm.12.18810.2217/nnm.12.188 ↗
39. 10.1042/bj2003076010.1042/bj20030760 ↗
40. 10.1016/j.anaerobe.2016.04.01110.1016/j.anaerobe.2016.04.011 ↗
41. 10.1016/S0041-0101(01)00164-710.1016/S0041-0101(01)00164-7 ↗
42. 10.1128/msphere.00276-2210.1128/msphere.00276-22 ↗
43. 10.1021/acs.molpharmaceut.4c0120510.1021/acs.molpharmaceut.4c01205 ↗
44. 10.1517/17425255.1.2.17510.1517/17425255.1.2.175 ↗
45. 10.3389/fbioe.2020.52401810.3389/fbioe.2020.524018 ↗
46. 10.1016/j.ijbiomac.2025.13963510.1016/j.ijbiomac.2025.139635 ↗
47. 10.1016/j.bbamem.2013.04.01210.1016/j.bbamem.2013.04.012 ↗
48. 10.1021/jz500794d10.1021/jz500794d ↗
49. 10.1002/adfm.20210091410.1002/adfm.202100914 ↗
50. 10.1002/smll.20200188510.1002/smll.202001885 ↗
51. 10.1371/journal.pone.028947310.1371/journal.pone.0289473 ↗
52. 10.1074/jbc.M20954820010.1074/jbc.M209548200 ↗
53. 10.1021/acsabm.3c0065910.1021/acsabm.3c00659 ↗
54. 10.1208/s12249-022-02424-410.1208/s12249-022-02424-4 ↗
55. 10.2217/nnm.09.9810.2217/nnm.09.98 ↗
56. 10.1016/S0014-5793(00)01744-010.1016/S0014-5793(00)01744-0 ↗
57. 10.1016/j.jconrel.2005.07.00810.1016/j.jconrel.2005.07.008 ↗
58. 10.1111/exd.1272810.1111/exd.12728 ↗
59. 10.1124/jpet.115.22539110.1124/jpet.115.225391 ↗
60. 10.3109/10717544.2015.105053010.3109/10717544.2015.1050530 ↗
61. 10.1016/j.bcp.2010.01.01010.1016/j.bcp.2010.01.010 ↗
62. 10.1021/acsami.4c2078410.1021/acsami.4c20784 ↗
63. 10.3389/fmed.2020.0018310.3389/fmed.2020.00183 ↗
64. 10.1111/ddg.1381110.1111/ddg.13811 ↗
65. 10.1111/j.1524-4725.2005.3172910.1111/j.1524-4725.2005.31729 ↗
66. 10.1016/j.diff.2017.09.00410.1016/j.diff.2017.09.004 ↗
67. 10.1016/j.bbamem.2010.07.01410.1016/j.bbamem.2010.07.014 ↗
68. 10.1038/nbt.150410.1038/nbt.1504 ↗
69. 10.1007/s00011-017-1065-z10.1007/s00011-017-1065-z ↗
70. 10.1007/82_2011_16910.1007/82_2011_169 ↗
71. 10.3389/fimmu.2017.0194110.3389/fimmu.2017.01941 ↗
72. 10.1016/j.jddst.2025.10681310.1016/j.jddst.2025.106813 ↗
73. 10.3390/pharmaceutics1511263210.3390/pharmaceutics15112632 ↗
74. 10.1021/acs.langmuir.4c0312310.1021/acs.langmuir.4c03123 ↗
75. 10.3390/biom1403032010.3390/biom14030320 ↗
76. 10.1007/978-981-13-3588-4_110.1007/978-981-13-3588-4_1 ↗
77. 10.1016/j.ijbiomac.2025.14773010.1016/j.ijbiomac.2025.147730 ↗
78. 10.3390/pharmaceutics1401019210.3390/pharmaceutics14010192 ↗
79. 10.1002/jps.2127710.1002/jps.21277 ↗
80. 10.1615/CritRevTherDrugCarrierSyst.201300695510.1615/CritRevTherDrugCarrierSyst.2013006955 ↗
81. 10.3390/pharmaceutics1504119710.3390/pharmaceutics15041197 ↗
82. 10.1021/acssuschemeng.1c0425610.1021/acssuschemeng.1c04256 ↗
83. 10.1021/acssuschemeng.0c0834510.1021/acssuschemeng.0c08345 ↗
84. 10.1016/j.jconrel.2020.08.00710.1016/j.jconrel.2020.08.007 ↗
85. 10.1016/j.ejpb.2024.11441010.1016/j.ejpb.2024.114410 ↗
86. 10.1016/j.ijpharm.2026.12658510.1016/j.ijpharm.2026.126585 ↗